Therapeutic Effect of PBF-680 in Patients With COPD
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation
and the lung function of patients with COPD on top of the standard medication. The effects of
PBF-680 administration will also be examined with regards to symptom improvement and safety
measures.One oral dose of PBF-680 or placebo will be administered daily for 4 weeks after
randomization. The treatments will be administered double-blind with the Investigator and
patient unaware of the treatment identity. A total of 102 COPD patients, either male or
female, aged 40 to 80 years (inclusive) will be randomized.